To explore the effects of the genetic background on the characteristics of wboA gene deletion rough mutants generated from different parent Brucella sp. strains, we constructed the rough-mutant strains Brucella melitensis 16 M-MB6, B. abortus 2308-SB6, B. abortus S19-RB6, and B. melitensis NI-NB6 and evaluated their survival, pathogenicity, and induced protective immunity in mice and sheep. In mice, the survival times of the four mutants were very different in the virulence assay, from less than 6 weeks for B. abortus S19-RB6 to 11 weeks for B. abortus 2308-SB6 and B. melitensis NI-NB6. However, B. abortus S19-RB6 and B. melitensis 16 M-MB6, with a shorter survival time in mice, offered better protection against challenges with B. abortus 2308 in protection tests than B. abortus 2308-SB6 and B. melitensis NI-NB6. It seems that the induced protective immunity of each mutant might not be associated with its survival time in vivo. In the cross-protection assay, both B. melitensis 16 M-MB6 and B. abortus S19-RB6 induced greater protection against homologous challenges than heterologous challenges. When pregnant sheep were inoculated with B. abortus S19-RB6 and B. melitensis 16 M-MB6, B. abortus S19-RB6 did not induce abortion, whereas B. melitensis 16 M-MB6 did. These results demonstrated the differences in virulence, pathogenicity, and protective immunity in vivo in the wboA deletion mutants from genetically different parent Brucella spp. and also indicated that future rough vaccine strain development could be promising if suitable parent Brucella strains and/or genes were selected.
B
rucella spp. are Gram-negative, facultative, intracellular bacteria that cause brucellosis (1) , which results in abortion and decreased milk production in animals and often induces fatigue and disabling sequelae in humans (2) .
Successful control and eradication of brucellosis depends on animal vaccinations, serological examinations, and the slaughter of infected animals, followed by destruction of the carcasses (3) . Live Brucella vaccines (B. abortus S19 for cattle and B. melitensis Rev.1 and B. suis S2 for cattle, sheep, and goats) induce effective immune protection against brucellosis for 4 years or more (4) (5) (6) , but vaccination with the three vaccines may cause abortion in pregnant animals (7) (8) (9) . Meanwhile, all three vaccines carry a bacterial surface antigen with an immunodominant region (O-polysaccharide [OPS] ), which persistently induces antibodies that interfere with the diagnosis of brucellosis. Thus, a novel, safe vaccine without the immunodominant OPS antigens is urgently needed for brucellosis eradication campaigns.
Many scientists have endeavored to improve current vaccine strains or to design novel vaccines that are devoid of OPS (rough lipopolysaccharide [LPS] ) and with satisfactory immunogenic properties (3) . One of the best-known rough vaccine strains is B. abortus RB51, a highly attenuated rough strain evaluated in mice, cattle, and bison that does not interfere with diagnosis and retains the capacity to induce protection (10) (11) (12) . Another attenuated rough strain, B. melitensis B115, also confers significant protective immunity in mice against the challenge of B. melitensis 16 M, B. ovis, and B. abortus 2308, equivalent to what is provided by B. melitensis Rev.1 (13, 14) . A different attenuated live rough vaccine strain, B. abortus 45/20, confers protection in cattle, but the vaccine strain easily reverts to smooth pathogenic forms in vivo (12, 15) . However, it was reported that the protective immunity induced by rough Brucella mutants was inferior to that induced by the smooth vaccine strains in sheep and goats, and several researchers started to question the feasibility of developing rough Brucella vaccine strains (16, 17) . Consequently, the suitability of rough mutants for live-vaccine development remains a topic of debate.
Previous studies on the virulence and induced protective immunity of the wboA gene deletion rough mutants was performed using Brucella spp. with various genetic backgrounds and under different experimental conditions, which made it difficult to compare the results. In this study, we selected the wboA gene, a model gene that encodes a glycosyltransferase responsible for OPS polymerization. We then evaluated the virulence, pathogenicity, and induced protective immunity of four rough mutants derived from different parent strains under the same experimental conditions. These results will be useful to evaluate the effects of genetic backgrounds on the characteristics of wboA gene deletion rough mutants generated from the different parent Brucella spp.
MATERIALS AND METHODS
Bacterial strains and media. The virulent B. abortus 2308, B. melitensis 16 M, and B. canis RM6/66 and the vaccine strain B. abortus S19 were all kindly donated by Qianni He (Institute of Veterinary Research, Xinjiang Academy of Animal Sciences, China). The strains mentioned above were originally collected and preserved in the Chinese Veterinary Culture Collection Center (CVCC). The epidemic strain B. melitensis NI was isolated from an aborted bovine fetus from Inner Mongolia by our laboratory. This strain, also referred to as the smooth virulent B. melitensis strain biovar 3, induced abortion in pregnant cattle, sheep, and goats. The complete NI genomes were sequenced. All Brucella strains, including the parent strains and the derived mutants, were routinely grown in tryptic soy broth (TSB) or tryptic soy agar (TSA) at 37°C. Escherichia coli stains were grown on Luria-Bertani (LB) plates overnight at 37°C, with or without supplemental ampicillin (100 mg/liter) and chloromycetin (30 mg/liter) ( Table 1 ). All work with live virulent Brucella strains was performed in biosafety level 3 facilities at China Agricultural University.
Animals. Four-to 6-week-old female BALB/c mice were purchased from Weitong Lihua Laboratory Animal Services Centre (Beijing, China), bred in individually ventilated cage rack systems, and subsequently transferred to the biosafety level 3 facilities of China Agricultural University at the beginning of the experiments. Pregnant female sheep at 100 to 120 days of gestation were obtained from brucellosis-free regions and determined to be seronegative with the brucellosis Rose-Bengal plate agglutination test (RBT) (9) and a standard tube agglutination test (SAT). The animals were housed in restricted-access large-animal isolation facilities. At the end of the experiments, all of the animals were euthanized with an animal-culling device and disposed of according to relevant national regulations. All experiments involving animals followed the regulations enacted by the Beijing Administration Office of Laboratory Animals.
Construction of wboA deletion mutants and their complementary strains. To construct the recombinant plasmid for deleting the wboA gene (the accession numbers of the wboA genes in the genomes of B. abortus 2308, B. melitensis 16 M, B. melitensis NI, and B. abortus S19 are BAB1_0999, BMEI0998, BMNI_I0963, and BabS19_I09300, respectively), the 5= and 3= fragments flanking the gene of interest were amplified with the primers shown in Phenotypic characterization of the mutants. The phenotypes of the mutants and their complementation strains were characterized by coagglutination of the killed bacterial suspensions with the acriflavine solution and the antisera against smooth and rough Brucella strains and by colony staining with crystal violet solution (21) . B. abortus 2308 (smooth) and B. canis RM6/66 (rough) were used as phenotype controls.
Virulence in BALB/c mice. Twenty-five mice were intraperitoneally inoculated with a dose of 10 6 CFU in 0.1 ml phosphate-buffered saline (PBS) for each strain (including the rough mutants, the complementation strains, and the parent strains). Another 25 mice received 0.1 ml PBS per mouse as a control. Five infected mice from each infected group or from the control group were randomly selected and euthanized via carbon dioxide asphyxiation at 1, 3, 6, 9, and 11 weeks postinoculation. At each time point, spleens were collected aseptically, homogenized in 1 ml of PBS, and then serially diluted (1/10, 1/100, and 1/1,000). A 200-l aliquot of each dilution and undiluted spleen homogenates were plated on TSA plates, 5= AAGCTTTCATGCCGCTGCCCTCACG 3= (HindIII) wboA operon incubated for 3 to 5 days at 37°C with 5% (vol/vol) CO 2 , and checked daily for growth. The bacteria recovered from the spleens were enumerated to evaluate the survival of each strain in mice (20, 22) . The results are presented as the mean number of CFU per spleen Ϯ standard deviation (SD) in each group. If no bacteria grew in the undiluted homogenized sample, the spleen was assumed to contain less than 5 bacteria, below the limit of detection of 5 CFU/spleen. (9) . Five mice were intraperitoneally inoculated at a dose of 10 6 CFU/mouse for each rough mutant or the vaccine strain B. abortus S19, respectively. Another five mice were intraperitoneally inoculated with 0.1 ml PBS as a control. Each mouse was challenged with 2 ϫ 10 5 CFU of the wild-type strain B. abortus 2308 at 14 weeks after vaccination. Two weeks later, the challenged mice were euthanized as described above. Spleens were collected and homogenized in 1 ml of PBS, serially diluted, and plated onto TSA. The challenged bacterial burden of the spleen was used to measure the protective immunity index.
Protection test in mice. Experiments were performed according to the procedure in the Manual of Diagnostic Tests and Vaccines for Terrestrial Animals
Cross-protection test in mice. The mutants that conferred a high level of protection in the protection test were selected for a cross-protection assay. Fifteen mice were intraperitoneally vaccinated at a dose of 10 6 CFU/ mouse for B. abortus S19-RB6 or B. melitensis 16 M-MB6. Another 15 mice were intraperitoneally inoculated with 0.1 ml of PBS as a control. At 12 weeks postinoculation, five vaccinated mice from each group were randomly challenged at a dose of 2 ϫ 10 5 CFU/mouse with B. abortus 2308, B. melitensis 16 M, or B. melitensis NI. Two weeks later, the challenged mice were euthanized as described above. The spleens were collected, homogenized in 1 ml of PBS, serially diluted, and plated on TSA. The challenged bacterial burden of the spleen was used to measure the protective immunity index.
Pathogenicity study in sheep. To compare the pathogenicities of B. abortus S19-RB6 and B. melitensis 16 M-MB6 with that of B. melitensis 16 M, the three strains were subcutaneously inoculated into five pregnant female sheep (100 to 120 days of gestation on average) at a dose of 10 9 CFU, which is considered the standard dose of B. melitensis Rev.1 vaccine for the immunization of sheep and goats (9) . The inoculated sheep were observed daily until abortion or delivery, and the lambs were euthanized immediately after birth. Throughout the period of observation, samples of afterbirths, including lungs, livers, spleens, and abomasal fluid, were aseptically collected from the aborted fetuses and lambs for bacteriological examination. Approximately 30 days after delivery, the sheep were euthanized and necropsied. Samples of the liver, spleen, mammary gland, supramammary lymph nodes, and parotid lymph nodes were collected for bacteriological examination. Afterward, the samples were aseptically removed from storage bags, submerged in 70% ethanol, and placed on a sterile petri plate. Approximately 0.5 g of tissue was aseptically extracted from each sample. Each section was then homogenized in a 50-ml sterile tube containing 1 ml of PBS, and 200 l of the homogenates was plated on TSA. The plates were incubated for 3 to 5 days at 37°C with 5% (vol/vol) CO 2 and checked daily for growth. Animals were considered infected based upon the presence of Ն1 CFU of Brucella in any tissue (23) .
Serological tests. To evaluate the antibody response induced by B. abortus S19-RB6 and B. melitensis 16 M-MB6, a sample of approximately 5 ml of blood was collected from the jugular vein of each vaccinated sheep at 7, 15, 30, 45, and 60 days postinoculation. The presence of OPS-specific antibodies in the sera was determined by the smooth Brucella antigen (from the China Institute of Veterinary Drug Control) according to the SAT procedure (21, 24) . To detect antibodies against rough LPS antigens, SAT was performed with the rough Brucella antigen (from the Chinese Centers for Disease Control Prevention) based on the same procedure.
Statistical analysis. A Student's t test was performed to analyze the data from the mouse virulence and protection experiments, and a P value of Ͻ0.05 was considered significant.
Nucleotide sequence accession numbers. The GenBank accession numbers of the complete NI genome sequence are CP002931 and CP002932.
RESULTS

Construction of rough
Brucella wboA deletion mutants. Brucella wboA gene deletion mutants were constructed via a doublerecombination event and confirmed by PCR with the primers in Table 2 ( Fig. 1) and by sequencing analysis (data not shown). Genetic complementation strains corresponding to each mutant were constructed by electroporating pBBRwboA into B. abortus 2308-SB6, B. abortus S19-RB6, B. melitensis 16 M-MB6, and B. melitensis NI-NB6. The four mutants were determined to be rough phenotypes based on the results of the coagglutination assay, crystal violet colony staining, and the acriflavine agglutination assay, whereas the genetic complementation strains CB. abortus 2308-SB6, CB. abortus S19-RB6, CB. melitensis 16 M-MB6, and CB. melitensis NI-NB6 regained their smooth phenotype. This confirmed that the four wboA deletion mutants and their corresponding genetic complementation strains were successfully constructed.
Virulence differences in wboA deletion mutants derived from different genetic backgrounds. We further determined the in vivo survival times and bacterial loads in mice harboring the four wboA deletion mutants. The numbers of viable bacteria recovered from the spleens of B. abortus 2308-SB6-, B. melitensis NI-NB6-, B. melitensis 16 M-MB6, and B. abortus S19-RB6-inoc- ulated mice were found to be much lower than those from mice infected with the respective parent strains. As shown in Fig. 2A , the mutant B. abortus S19-RB6 was not detected from the inoculated mice at 6 weeks postinoculation, whereas the B. abortus S19 parent strain persisted for 11 weeks (Fig. 2B) . B. melitensis NI-NB6 and B. melitensis 16 M-MB6 were completely cleared at 9 weeks postinoculation, whereas B. abortus 2308-SB6 had the longest survival time of all the mutants and persisted for 11 weeks in mice (Fig. 2) . At the end of the test, B. melitensis 16 M, B. abortus 2308, and B. melitensis NI were recovered at 10 4 CFU, 10 5 CFU, and 10 4 CFU, respectively, from the spleens of the inoculated mice. The virulence levels of the corresponding complementation strains were similar to that of the parent strains (data not shown). These results indicated that the four Brucella wboA deletion mutants were attenuated in mice and that the virulence levels were significantly different in the wboA deletion mutants derived from different genetic backgrounds.
Differences in protective efficacy of wboA deletion mutants with different genetic backgrounds. To evaluate the potential protective immunity induced by the mutants against the virulentstrain challenge, the numbers of challenge strains recovered from the spleens of all the vaccinated mice were compared to the numbers recovered from the control mice. The challenge strain B. abortus 2308 was expected to be recovered in all of the control mice. Protective immunity was expressed as log 10 units of protection (25) . As shown in Table 3 , B. abortus S19-RB6 and B. melitensis 16 M-MB6 (1.53 and 1.42 protection units, respectively) conferred greater protection than B. melitensis NI-NB6 and B. abortus 2308-SB6 (0.82 and 0.90 protection units, respectively) (P Ͻ 0.05). Meanwhile, the challenge strain B. abortus 2308 was recovered in all of the challenge control mice, and there was a statistically significant difference (P Ͻ 0.05) between the mutant groups and the challenge control groups in protective immunity.
Cross-protection of B. melitensis 16 M-MB6 and B. abortus S19-RB6 mutants against challenge with different Brucella spp. To explore the cross-protective immunity induced by the rough mutants, B. melitensis 16 M-MB6-and B. abortus S19-RB-vaccinated mice were challenged with the virulent B. abortus 2308, B. melitensis 16 M, and B. melitensis NI. The virulent strains were recovered from the spleens of the challenged mice, and the results are presented in Pathogenicity of B. melitensis 16 M-MB6 and B. abortus S19-RB6 mutants in pregnant sheep. The pathogenicity of Brucella strains in pregnant ruminants includes persistent infection, stillbirth, and abortion (26) . In this study, two groups of pregnant sheep were inoculated with B. melitensis 16 M-MB6 and B. abortus S19-RB6. During nearly 3 months of observation, only one sheep (S3) aborted at 28 days after infection in the B. melitensis 16 M-MB6-inoculated group, whereas all four of the other sheep in this group and all of the B. abortus S19-RB6-inoculated sheep produced normal lambs 40 to 60 days postinoculation. Abortion was defined as the premature expulsion of a nonviable fetus, whereas premature live lambs, who were hypoactive and had difficulty sucking colostrum, were regarded as weak lambs (27) .
To determine the survival in vivo of B. melitensis 16 M-MB6 and B. abortus S19-RB6, bacteria from the maternal sheep, fetus, and lambs were recovered, and the animals with one or more isolated Brucella colonies in any tissue were considered bacteriologically positive. Our results showed that only the afterbirth and fetus from the aborted sheep in the B. melitensis 16 M-MB6-inoculated group was positive, and no mutant was recovered from the lambs and afterbirths of the normal delivered sheep at the time of euthanasia (Table 5 ). These results indicated that B. abortus S19-RB6 was a safe strain for pregnant sheep, whereas B. melitensis 16 M-MB6 remained somewhat pathogenic in the pregnant sheep.
Antibody responses in B. melitensis 16 M-MB6-and B. abortus S19-RB6-inoculated sheep. The antibody responses in the B. melitensis 16 M-MB6-and B. abortus S19-RB6-inoculated sheep are presented in Fig. 3 . In sheep inoculated with either B. melitensis 
DISCUSSION
In recent decades, numerous rough mutants have been generated by disrupting LPS synthesis genes, including wboA, wboB, wbkA, gmd, per, wzm, pgm, wa**, and manB core . However, none of these artificially constructed rough mutants induced protective immunity equivalent to that of B. melitensis Rev.1 in animal models (28 (31) . Therefore, these variations in experimental conditions pose difficulties in comparing the virulence and protective immunity conferred by these mutants, leaving questions about the novel rough vaccines unresolved.
In this study, B. melitensis 16 M, B. abortus 2308, B. abortus vaccine strain S19, and B. melitensis NI were used as the parent strains for the generation of wboA deletion rough mutants. In the mouse survival assays, the survival times were compared among the four mutants B. melitensis 16 M-MB6, B. abortus 2308-SB6, B. abortus S19-RB6, and B. melitensis NI-NB6 (Fig. 2) . T-cell-mediated immunity has been reported to be the primary mode of immune protection against Brucella (33) (34) (35) , and thus, the rough 6 CFU/mouse. Five mice per group were euthanized at 1, 3, 6, 9, and 11 weeks postinoculation, and the virulence of each strain was determined based on the number of CFU recovered from the spleen, which is expressed as the mean Ϯ SD (n ϭ 5) of individual log 10 CFU/spleen. In the cross-protection assay, B. melitensis 16 M-MB6 and B. abortus S19-RB6 were selected for use in both homologous and heterologous challenges, because they yielded better protection than the other two mutants in the protective-efficacy assay. However, both B. melitensis 16 M-MB6 and B. abortus S19-RB6 yielded only somewhat greater protection against homologous challenges than against heterologous challenges. A similar phenomenon was also observed by Winter in the evaluation of the protective efficacy of B. melitensis VTRM1 and B. suis VTRS1 (both wboA-disrupted mutants) in mice (32) . Moreover, B. abortus RB51 has been reported to induce good protective immunity against B. abortus in cattle (36) , but it is not effective against B. suis infection in cattle (37) and ovine brucellosis caused by either B. melitensis or B. ovis (38, 39) . Similar to the smooth vaccine strains, such as B. abortus S19 (which failed to protect heifers against experimental infection with B. suis biovar 1 [40] ), the rough Brucella mutants had differences in cross-protective immunity.
The results of pathogenicity examination indicated that not all of the Brucella spp. could be used as parent strains for generating safe vaccines. For instance, B. abortus S19-RB6, which was derived from the vaccine strain B. abortus S19, exhibited a high level of safety in pregnant sheep. However, the inoculation of pregnant sheep with B. melitensis 16 M-MB6 induced abortion in one of the five animals in this study, suggesting that this rough mutant was still somewhat pathogenic to pregnant animals. Since the glycosyltransferase encoded by wboA is responsible for OPS polymerization, we hypothesized that there are components other than OPS associated with the pathogenicity of Brucella in pregnant animals. In support of this hypothesis, available Brucella vaccines, such as B. abortus S19 and B. melitensis Rev.1, are attenuated in vivo but induce abortion when they are subcutaneously inoculated into pregnant animals, and a naturally occurring rough virulent strain, Brucella ovis, can induce abortion in ewes (41) . As the transplacental transmission mechanism of Brucella is not clearly understood, it is necessary to identify factors affecting the prevalence of abortion for the development of safer Brucella vaccines. Therefore, in specific regions and countries, the generation of a good rough vaccine may depend on the genetic backgrounds of the parent strains and/or the epidemic Brucella strains, as each vaccine provides effective protection against a specific Brucella species in the preferred host (14) .
In conclusion, there were noticeable differences in virulence, pathogenicity, and induced immunity protection among the four wboA deletion mutants generated from different parent strains with diverse genetic backgrounds. Although the wboA mutants were not ideal vaccine candidates in this study, our results suggested that it is necessary to consider the parent strains (the reference strains or the epidemic Brucella strains in the different animal herds), as well as the desired target genes, when developing novel rough Brucella vaccines.
